RXPA 380 manufacturers
- RXPA 380
-
- $2780.00
-
2026-07-27
- CAS:564479-79-4
- Purity:
- Supply Ability: 10g
|
| | RXPA 380 Basic information |
| Product Name: | RXPA 380 | | Synonyms: | RXPA 380;IMPJIKIXNAGRCR-SFOGZRFBSA-N;L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- | | CAS: | 564479-79-4 | | MF: | C33H36N3O7P | | MW: | 617.63 | | EINECS: | | | Product Categories: | | | Mol File: | 564479-79-4.mol |  |
| | RXPA 380 Chemical Properties |
| Boiling point | 996.6±65.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | pka | 3.05±0.40(Predicted) |
| | RXPA 380 Usage And Synthesis |
| Description | RXPA380 is a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. | | Uses | RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM[1]. | | in vivo | RXPA 380 (0.9-30 mg/kg; i.v.; once) inhibits ACE activity in mice[1]. | Animal Model: | Male C57BL6/J mice[1] | | Dosage: | 0.9, 3, 10, and 30 mg/kg | | Administration: | Intravenous infuse for 30 minutes | | Result: | Induced a dose-dependent decrease of the Ang II/Ang I ratio. Blocked the cleavage of exogenously administered bradykinin. |
| | References | [1] Georgiadis D, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003 Jul 25;93(2):148-54. DOI:10.1161/01.RES.0000081593.33848.FC |
| | RXPA 380 Preparation Products And Raw materials |
|